The Clinical Applications of Functional Profiling CSRA: Lung Cancer
March 19, 2010 Leave a comment
Lung cancer, with 215,000 new diagnoses and 162,000 deaths in the United States each year, represents the leading cause in cancer death in the US. Average response rates of 30 percent and median survivals of 12 months remain static over decades. The five-year survival of 15 percent for this disease has not changed in 50 years.
While better surgical techniques and the introduction of new drugs have improved the one-year survival from 35 percent to 41 percent in the last 20 years, this has not had a major impact on overall survival.
Few diseases offer the opportunity to meaningfully improve cancer survival like lung cancer. A 25 percent improvement in survival in lung cancer would be the numerical equivalent of curing breast cancers outright. Recognizing this opportunity, we have made lung cancer a principal focus of the functional profiling platform. Our current IRB approved clinical protocol in non-small cell lung cancer applies our functional profiling platform to select from among the commercially available FDA approved compendium listed drugs, in metastatic non-small cell lung cancer. The results of our study have been submitted to national meetings. To date, our approach has more than doubled the objective response rate to 69 percent, improved the time to progression, provided over one-third of our stage IV patients the capacity to undergo definitive radiation or surgery, and extended the lives of some stage IV patients to five or more years. By exploring the first line use of the newer targeted agents, many patients are achieving durable responses without ever being exposed to classic chemotherapeutic drugs. It is our intent to make these laboratory analyses available to all newly diagnosed and relapsed lung cancer patients.